Physician profile
Tyler Patten
NPI 1386488971
$2,430.76
in general payments reported to CMS, 2019-2025
22 companies · $2,151 in 2025
The $2,151 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $280 · 2025: $2,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $429.54 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $264.24 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $240.93 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $206.38 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $197.33 | 2025 | Spravato |
| Neurocrine Biosciences, INC. | $178.03 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $137.23 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.34 | 2025 | Caplyta |
| Indivior INC. | $87.54 | 2025 | Sublocade |
| Axsome Therapeutics, INC. | $77.35 | 2025 | Sunosi, Auvelity |
| Ironshore Pharmaceuticals INC. | $66.52 | 2024 | |
| Biogen, INC. | $65.84 | 2025 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $64.08 | 2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $43.96 | 2025 | Jornay Pm |
| Alkermes, INC. | $43.37 | 2025 | Aristada, Lybalvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $37.75 | 2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $37.48 | 2025 | Qelbree |
| Sanofi-Aventis U.S. LLC | $30.40 | 2025 | |
| Tris Pharma INC | $30.24 | 2025 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.77 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.53 | 2025 | Trintellix |
| Tempus Ai, INC | $21.91 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Patten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.